About this trial
This clinical study to evaluate sonobiopsy is significant because sonobiopsy will fundamentally enhance the clinician's insight into the molecular features of an intracranial lesion to tailor treatment approaches and optimize outcomes. In addition to the standard diagnostics of anatomic imaging and surgical histology, sonobiopsy has the potential to become the third pillar for brain tumor management by radically advancing the ability to easily and regularly acquire tumor genetic and molecular signatures. This enhanced capability will have a dramatic impact on patient survival and quality of life.
Eligibility criteria
Qualifiers
Must be newly diagnosed with a lesion in the brain with imaging characteristics consistent with glioblastoma multiforme. Scan must have occurred no more than 28 days prior to enrollment.
Lesion must be > 3 cm in maximal dimension on MRI.
Lesion must be in the supratentorial space within 5 cm of the cortical surface.
Lesion must be gadolinium enhancing.
Disqualifiers
Contraindication to MRI.
Previous cranial surgery.
Previous history of cancer and/or cancer treatments.
Coagulopathy within 14 days of enrollment defined as PT/PTT outside of normal parameters and platelets < 100,000/mcL.
Trial design
Treatments tested in this trial
- Sonobiopsy
- Research blood
- Cancer Personalized Profiling
- Definity®
Treatment groups
Sponsors and collaborators
Washington University School of Medicine
Lead sponsor
National Cancer Institute (NCI)
Collaborator